The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Tsai, G.
* Articles by Coyle, J. T.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Tsai, G.
* Articles by Coyle, J. T.
Related Collections
* Neurodegeneration
* Neurotransmitters
* Schizophrenia Spectrum Disorders
* Other Neuroleptics
Am J Psychiatry 155:1207-1213, September 1998
©Copyright 1998 American Psychiatric Association


Regular Article

Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia

Guochuan Tsai, M.D., Ph.D., Donald C. Goff, M.D., Robert W. Chang, B.S., James Flood, Ph.D., Lee Baer, Ph.D., and Joseph T. Coyle, M.D.

Objective: Tardive dyskinesia is a movement disorder affecting 20%–40% of patients treated chronically with neuroleptic drugs. The dopamine supersensitivity hypothesis cannot account for the time course of tardive dyskinesia or for the persistence of tardive dyskinesia and the associated structural changes after neuroleptics are discontinued. The authors hypothesized that neuroleptics enhance striatal glutamatergic neurotransmission by blocking presynaptic dopamine receptors, which causes neuronal damage as a consequence of oxidative stress.Method: CSF was obtained from 20 patients with schizophrenia, 11 of whom had tardive dyskinesia. Markers for oxidative stress, including superoxide dismutase, lipid hydroperoxide, and protein carbonyl groups, and markers for excitatory neurotransmission, including N-acetylaspartate, N-acetylaspartylglutamate, aspartate, and glutamate, were measured in the CSF specimens. Patients were also rated for tardive dyskinesia symptoms with the Abnormal Involuntary Movement Scale.Results: Tardive dyskinesia patients had significantly higher concentrations of N-acetylaspartate, N-acetyl­aspartylglutamate, and aspartate in their CSF than patients without tardive dyskinesia when age and neuroleptic dose were controlled for. The significance of the higher levels of protein-oxidized products associated with tardive dyskinesia did not pass Bonferroni correction, however. Tardive dyskinesia symptoms correlated positively with markers of excitatory neurotransmission and protein carbonyl group and negatively with CSF superoxide dismutase activity.Conclusions: These findings suggest that there are elevated levels of oxidative stress and glutamatergic neurotransmission in tardive dyskinesia, both of which may be relevant to the pathophysiology of tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-1213




This article has been cited by other articles:


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
S. Kropp, V. Kern, K. Lange, D. Degner, G. Hajak, J. Kornhuber, E. Ruther, H. M. Emrich, U. Schneider, and S. Bleich
Oxidative Stress During Treatment With First- and Second-Generation Antipsychotics
J Neuropsychiatry Clin Neurosci, May 1, 2005; 17(2): 227 - 231.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
A. E Khalifa
Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats
Human and Experimental Toxicology, September 1, 2004; 23(9): 439 - 445.
[Abstract] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
C. A. TAMMINGA, A. C. LAHTI, D. R. MEDOFF, X.-M. GAO, and H. H. HOLCOMB
Evaluating Glutamatergic Transmission in Schizophrenia
Ann. N.Y. Acad. Sci., November 1, 2003; 1003(1): 113 - 118.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
W. M. Glazer, S. W. Woods, and D. Goff
Should Sisyphus Have Taken Melatonin?
Arch Gen Psychiatry, November 1, 2001; 58(11): 1054 - 1055.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org